Filing Details
Outlook Therapeutics, Inc. (NASDAQ:OTLK) filed a Form 8-K with the Securities and Exchange Commission on June 26, 2026, disclosing a material event.
8k filedNASDAQ:OTLK
Outlook Therapeutics, Inc. (OTLK) Reports Material Event to SEC
Filing Details Outlook Therapeutics, Inc. (NASDAQ:OTLK) filed a Form 8-K with the Securities and Exchange Commission on June 26, 2026, disclosing a material event. Market Context…
Market Context
Outlook Therapeutics, Inc.'s stock currently trades at $1.71 with a market capitalization of $89.3M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Outlook Therapeutics, Inc.'s stock.
All SEC filings for Outlook Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View OTLK Stock Page
Frequently Asked Questions
Where can I read OTLK's SEC filings?
Browse all filings on our OTLK SEC filings page.
What types of SEC filings does Outlook Therapeutics, Inc. file?
Public companies like Outlook Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.